Related Experiment Video

Updated: Feb 21, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

PCSK9 inhibitors and managing cost in the managed care setting

Sheila L Stadler, Thomas J Cook

    The American Journal of Managed Care
    |October 6, 2017
    PubMed

    Insights

    New proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a novel approach to significantly reduce low-density lipoprotein cholesterol (LDL-C) in high-risk patients. Further evaluation of their cost-effectiveness and impact on cardiovascular events is crucial for managed care.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Biochemistry

    Background:

    • Hypercholesterolemia poses significant cardiovascular risks, particularly in patients with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH).
    • Maximally tolerated statin therapy remains a cornerstone for LDL-C reduction, but many patients require additional lipid-lowering strategies.

    Purpose of the Study:

    • To evaluate the role of a new class of drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, in reducing low-density lipoprotein cholesterol (LDL-C).
    • To assess the mechanism of action and potential benefits of PCSK9 inhibitors compared to standard therapies for hypercholesterolemia.

    Main Methods:

    • Review of current literature on PCSK9 inhibitors, including approved monoclonal antibodies alirocumab and evolocumab.
    • Analysis of the mechanism by which PCSK9 inhibitors lower LDL-C, distinct from traditional statin therapy.

    Main Results:

    • PCSK9 inhibitors demonstrate substantial reductions in serum LDL-C levels.
    • These agents offer a novel therapeutic pathway for patients with refractory hypercholesterolemia.

    Conclusions:

    • PCSK9 inhibitors represent a promising therapeutic option for managing hypercholesterolemia in high-risk populations.
    • Careful consideration of cost-effectiveness and clinical event reduction is necessary for widespread adoption in managed care settings.

    More Related Videos

    Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease06:16

    Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

    Published on: August 9, 2024

    981
    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

    An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

    Published on: March 30, 2014

    19.4K

    Related Concept Videos

    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    29
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
    473
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
    25
    Methods of Documentation VI: Case Management Model01:15

    Methods of Documentation VI: Case Management Model

    The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
    For example, a patient with a chronic...
    974
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    321
    Pharmacokinetics: Drug–Drug Interactions01:25

    Pharmacokinetics: Drug–Drug Interactions

    Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
    508